Immunomedics’ Epratuzumab Enters Phase III Trials For Lupus
This article was originally published in The Pink Sheet Daily
Executive Summary
The B-cell modulator is beginning pivotal trials in patients with moderately active systemic lupus erythematosus and in patients with severe SLE flares. Other investigational lupus therapies have been held up by Phase III failures.
You may also be interested in...
UCB To Jump-Start Ongoing Lupus Studies For Immunomedics’ Epratuzumab
UCB licenses rights to epratuzumab for all autoimmune disease indications for roughly $208 mil. plus royalties.
UCB To Jump-Start Ongoing Lupus Studies For Immunomedics’ Epratuzumab
UCB licenses rights to epratuzumab for all autoimmune disease indications for roughly $208 mil. plus royalties.
Human Genome Sciences Plans to Move LymphoStat-B To Phase III
Firm believes it can proceed with Phase III trials of the lupus agent based on subpopulation findings despite its failure to meet primary endpoints in Phase II.